首页> 外文期刊>Peptides: An International Journal >Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.
【24h】

Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.

机译:血管肽酶抑制剂omapatrilat对急性心肌梗死大鼠心脏内源激肽的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

The purposes of this study were to evaluate and to compare the effects of simultaneous angiotensin-converting enzyme (ACE) and neutral endopeptidase 24.11 (NEP) inhibition by the vasopeptidase inhibitor omapatrilat (1 mg. kg(-1). day(-1)) with those of the selective ACE inhibitor enalapril (1 mg. kg(-1). day(-1)) on survival, cardiac hemodynamics, and bradykinin (BK) and des-Arg(9)-BK levels in cardiac tissues 24 h after myocardial infarction (MI) in rats. The effect of the co-administration of both B(1) and B(2) kinin receptor antagonists (2.5 mg. kg(-1). day(-1) each) with metallopeptidase inhibitors was also evaluated. The pharmacological treatments were infused subcutaneously using micro-osmotic pumps for 5 days starting 4 days before the ligation of the left coronary artery. Immunoreactive kinins were quantified by highly sensitive and specific competitive enzyme immunoassays. The post-MI mortality of untreated rats with a large MI was high; 74% of rats dying prior to the hemodynamic study. Mortality in the other MI groups was not significantly different from that of the untreated MI rats. Cardiac BK levels were not significantly different in the MI vehicle-treated group compared with the sham-operated rats. Both omapatrilat and enalapril treatments of MI rats significantly increased cardiac BK concentrations compared with the sham-operated group (P < 0.05). However, cardiac BK levels were significantly increased only in the MI omapatrilat-treated rats compared with the MI vehicle-treated group (P < 0.01). Cardiac des-Arg(9)-BK concentrations were not significantly modified by MI, and MI with omapatrilat or enalapril treatment compared with the sham-operated group. The co-administration of both kinin receptor antagonists with MI omapatrilat- and enalapril-treated rats had no significant effect on cardiac BK and des-Arg(9)-BK levels. Thus, the significant increase of cardiac BK concentrations by omapatrilat could be related to a biochemical or a cardiac hemodynamic parameter on early (24 h) post-MI state.
机译:这项研究的目的是评估并比较血管肽酶抑制剂omapatrilat(1 mg。kg(-1)。day(-1)对同时血管紧张素转换酶(ACE)和中性内肽酶24.11(NEP)的抑制作用。 )与选择性ACE抑制剂依那普利(1 mg。kg(-1)。day(-1))对存活率,心脏血流动力学以及心脏组织中缓激肽(BK)和des-Arg(9)-BK的影响24大鼠心肌梗死(MI)后h。还评估了B(1)和B(2)激肽受体拮抗剂(分别为2.5 mg。kg(-1)。day(-1))与金属肽酶抑制剂共同给药的效果。在结扎左冠状动脉前4天开始,用微渗透泵皮下输注药理作用5天。免疫反应激肽通过高度敏感和特异的竞争性酶免疫法定量。未治疗的大MI大鼠的MI后死亡率很高。在血液动力学研究之前,有74%的大鼠死亡。其他MI组的死亡率与未治疗的MI大鼠的死亡率无显着差异。与假手术大鼠相比,MI载体治疗组的心脏BK水平无显着差异。与假手术组相比,奥马帕多拉和依那普利治疗MI大鼠均显着增加了心脏BK浓度(P <0.05)。然而,与MI媒介物治疗组相比,仅在MI omapatrilat治疗的大鼠中心脏BK水平显着增加(P <0.01)。与假手术组相比,心肌梗死的des-Arg(9)-BK浓度没有被MI显着改变,而使用omapatrilat或enalapril治疗的MI则没有明显改变。两种激肽受体拮抗剂与奥马帕来拉定和依那普利治疗的大鼠共同给药对心脏BK和des-Arg(9)-BK水平无显着影响。因此,omapatrilat使心脏BK浓度显着增加可能与MI后早期(24 h)的生化或心脏血液动力学参数有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号